SOLIGENIX, INC. Accrued Liabilities, Current
SOLIGENIX, INC. (SNGX) had Accrued Liabilities, Current of $2.06 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-07
- 2026-06-30: Accrued Liabilities, Current $2.06M.
- 2026-03-31: Accrued Liabilities, Current $2.63M.
- 2025-12-31: Accrued Liabilities, Current $1.98M.
- 2025-09-30: Accrued Liabilities, Current $2.03M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $2.06M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $2.63M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $1.98M 10-Q · filed 2026-08-07 | |
| 2025-09-30 | $2.03M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $2.78M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $3.12M 10-Q · filed 2025-08-14 | $3.40M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $2.36M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $1.36M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $1.70M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $2.60M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $2.42M 10-K · filed 2025-03-21 | |
| 2023-09-30 | $2.39M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $2.35M 10-Q · filed 2023-08-21 | |
| 2023-03-31 | $2.45M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $2.31M 10-K · filed 2024-03-15 | |
| 2022-09-30 | $2.24M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $2.44M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $2.59M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $2.96M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $2.72M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $2.46M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $2.96M 10-Q · filed 2022-05-13 | $2.41M 10-Q · filed 2021-05-18 |
| 2020-12-31 | $2.64M 10-K · filed 2022-03-29 | |
| 2020-09-30 | $2.65M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $3.16M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $3.33M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $3.16M 10-K · filed 2021-03-30 | |
| 2019-09-30 | $3.16M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $2.79M 10-Q · filed 2019-08-13 | |
| 2019-03-31 | $2.30M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $1.79M 10-K · filed 2020-03-30 | |
| 2018-09-30 | $1.98M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $1.73M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $1.61M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $1.14M 10-K · filed 2019-03-26 | |
| 2017-09-30 | $1.09M 10-Q · filed 2017-11-06 | |
| 2017-06-30 | $1.48M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $1.07M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $806.12K 10-K · filed 2018-03-15 | |
| 2016-09-30 | $1.08M 10-Q · filed 2016-11-10 | |
| 2015-12-31 | $1.51M 10-K · filed 2017-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |